🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣 New podcast! #HER2 dx & Tx in #NSCLC: Episode 1 👉 #MedOnc POV from Prof. Lopéz-Ríos 👉 #Pathology POV from Dr Das w/ the Oncology Brothers 📹 Highlights video below Full conversation + links to Spotify/Apple: cor2ed.com/lung-connect/p… Supported by an Independent Educational

🔎 Get the patient perspective Elaine Lynch has stage 4 metastatic #lungcancer driven by a rare alteration 📺She shares her story in this video, explaining: 🔸What it means to live with HER2 exon 20 mutated non-small cell lung cancer 🔸What other patients need to know

🧬Oncogene-addicted #NSCLC data from #ELCC25 Updates from: · MARIPOSA · SOHO-01 · ORCHARD · DESTINY-Lung03 See more: cor2ed.com/lung-connect/p… Supported by an Independent Educational Grant from Bayer #MedEd #Oncology #thoraciconcology 📺

🚨 New video podcast! 🚨 The HER2 diagnostic and treatment landscape in NSCLC: Navigating common treatment scenarios ➡️w/ Oncology Brothers, Dr Isabel Preeshagul & Dr Eric K. Singhi, MD Highlights in this post 📹 Full conversation on video/Spotify/Apple: cor2ed.com/lung-connect/p… Endorsed by

Do you have a #lungcancer diagnosis? In this #PatientSupport video, Elaine Lynch shares her story of being diagnosed with a rare type of non-small cell lung cancer, driven by a rare alteration📺 Elaine is Co-Chair of the Exon 20 Group in the UK. Find out more about the Exon

🩺A medical oncologist and a pathologist share their perspectives on identifying HER2-directed #NSCLC In Ep. 1 of this new podcast series, experts discuss: - The different #HER2 alterations & prevalence in NSCLC - Which techniques identify which HER2 alterations -

In #NSCLC, HER2-positivity includes: 👉 mutations 👉 amplifications 👉 overexpression It's important to distinguish HER2 muts from EGFR muts, particularly exon 20 insertions, in NGS results Dive into this topic in this podcast conversation from medical experts ⬇️ Listen on

Thanks for everything you and your colleagues do at Anschutz for rare lung cancer patients, Tejas. We are fascinated by your post about the incredibly exciting Abstract 8512 and the 63% ORR for AbbVie’s Temab-A/ABBV-400/telisotuzumab adizutecan and NCT05029882, amazing. When we

This is very good news—13% versus 66% on IRR: …ess-1455827-5472931.cloudwaysapps.com/subcutaneous-a…

Amy, it’s always a delight to meet with you. Excited about your new role at Summit and the impressive pan-tumor pipeline. They are so very lucky to have you! Lots of homework post-ASCO on my part in order to catch up and keep track!

Hot off the Press on Zipalertinib! Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology taihooncology.com/us/news/taiho-…

Congratulations to Taiho Oncology for REZ1 impressive data. No surprise for zipalertinib patients and care partners in the Exon 20 Group! Glad to see the CNS confirmation! taihooncology.com/us/news/taiho-…

BN-39643 represents the newest concept of EGFR TKI, higher potency than osimertinib, CNS penetration, covering classical, C797S, PACC, and ex20 mutations, so it prevents all EGFR dependent resistance.

BAY88 has its name now, sevabertinib 😀. We are actively enrolling globally for HER2-activating mutation treatment-naive NSCLC patients.

.Herbert Loong, MBBS, FASCO presents BAY088 (sevabertinib) cohort D/F. HER2 treatment naive/SACT naive. Cohort D, ORR=60.5% DOR 9.2mo (TKD ORR 65%). Cohort F, ORR 59%. AEs mostly GI/EGFR-related, 25% G3 diarrhea. Active drug but note skin/GI tox #ASCO25

Congrats to the amazing Helena Yu, Zosia Piotrowska, @CullinanTherapeutics, Taiho Oncology and all the patients and care partners as well as investigators/study team members who participated in REZILIENT-1! #LCSM

Not suprising, this is as we thought, but amazing that it was formally tested and done. Sorry..scalp cooling does not work for T-DXd and I would extrapolate to other #ADCs with long half lives. #hairloss #bcsm #ASCO25 #scalpcooling

A new study by the American Cancer Society Cancer Action Network finds the 340B program creates incentives for hospitals to use more expensive medications, thus increasing the amount cancer patients pay in deductibles, coinsurance, and for medications. Governor Tina Kotek, please veto

The misuse of the 340B prescription drug program means low-income and uninsured patients often pay full price when they should get vitally needed drugs at a discount. This is wrong! #HB2385 in Oregon makes a bad situation worse. Governor Tina Kotek, please veto #HB2385 #ORleg 2/3

The 340B prescription drug program is a prime example of a bloated federal program that fails to serve those it was meant to help: low-income and uninsured patients. #HB2385 in Oregon makes a bad situation worse. Governor Tina Kotek, please veto #HB2385 #ORleg 1/3